Our game-changing technology
Large surgical blood losses are still frequent and associated with mortality, prolonged hospitalizations, high costs, and reoperations. Leveraging its patented technology, GATT Technologies has developed the a platform that aims to be the next frontier in the global market of hemostats and sealants: our platform is faster, more effective, more versatile, and more cost effective than alternatives currently in the market. It addresses significant unmet needs in managing complex surgical bleeding.
GATT’s platform solutions address surgical bleedings where applying pressure or suturing is not feasible or sufficiently efficient. This need is increasing with the strong global growth in surgical procedures and the introduction and expansion of robotic and laparoscopic surgeries.
The estimated global market for hemostats and sealants is currently about $4B, growing at an estimated 7-10% per year.
GATT’s platform is designed to meet the growth in surgical procedures and the expansion of robotic and laparoscopic surgeries. Scalable low-cost production enables faster time to market capabilities for complex bleeding and leakage solutions.
GATT’s game-changing platform uses a synthetic (POx) polymer to improve surgical outcomes. Powered by this next-generation technology, our platform serves as a one-stop-shop of solutions providing hemostatic sealing during surgery where normal coagulation becomes a challenge.
Our first products will include a fast acting hemostatic and sealant patch, and a powder. In addition, GATT is expanding its portfolio to include spray and tape solutions. This comprehensive suite of products is designed to control bleeding in general, cardiovascular and lung surgeries, minimally invasive laparoscopic/robotic procedures and cases of intestinal anastomotic leakage. GATT is also developing solutions for bone regeneration, anti-adhesion, vascular and ophthalmology.